{
    "q": [
        {
            "docid": "12761009_3",
            "document": "Desformylflustrabromine . dFBr has been identified as a novel positive allosteric modulator of neuronal nicotinic acetylcholine receptor with sub-type specificity for heteromeric receptor with no effect on homomeric sub-type. A recent study has been published which describes the synthesis of water-soluble salts of dFBr and its action has been confirmed as selective potentiator of \u03b14\u03b22 nicotinic acetylcholine receptor responses by using two-electrode voltage clamp whole cell recordings. In the year 2002 it was reported that dFBr was cytotoxic on human colon cancer cell line HCT 116. Desformylflustrabromine has also been found to be a positive allosteric modulator for the \u03b12\u03b22 subtype of neuronal nicotinic acetylcholine receptor. Additionally it relieves the inhibition of both \u03b12\u03b22 and \u03b14\u03b22 Nicotinic Acetylcholine Receptors by \u03b2-Amyloid (1\u201342) Peptide. Thus Desformylflustrabromine can potentially be used in the treatment of Alzheimer's disease. Many of the deconstructed analogs of dFBr are reported to have a potentiating effect on the \u03b14\u03b22 receptors.",
            "score": 177.21900379657745
        },
        {
            "docid": "2103074_12",
            "document": "Epibatidine . Nicotinic acetylcholine receptors are found in the post-synaptic membranes of nerve cells. They propagate neurotransmission in the central and peripheral nervous system. When neurotransmitters bind to these receptors, ion channels open, allowing Na and Ca ions to move across the membrane. This depolarizes the post-synaptic membrane, inducing an action potential that propagates the signal. This signal will ultimately induce release of dopamine and norepinephrine, resulting in an antinociceptive effect on the organism. The usual neurotransmitter for nAChR is acetylcholine. However, other substances (such as epibatidine and nicotine) are also able to bind to the receptor and induce a similar, if not identical, response. Epibatidine has an extremely high affinity for nAChRs, depending on the receptor subtype, from 0.05\u00a0nM at the \u03b14\u03b22 subtype to 22\u00a0nM at the \u03b17 subtype. Affinity as well as efficacy (and thus also potency) are much higher than for nicotine.",
            "score": 280.9612190723419
        },
        {
            "docid": "38272_10",
            "document": "Nicotine . Nicotine is frequently used for its performance-enhancing effects on cognition, alertness, and focus. A meta-analysis of 41\u00a0double-blind, placebo-controlled studies concluded that nicotine or smoking had significant positive effects on aspects of fine motor abilities, alerting and orienting attention, and episodic and working memory. A 2015 review noted that stimulation of the \u03b14\u03b22 nicotinic receptor is responsible for certain improvements in attentional performance; among the nicotinic receptor subtypes, nicotine has the highest binding affinity at the \u03b14\u03b22 receptor (k=1\u00a0), which is also the biological target that mediates nicotine's addictive properties. Nicotine has potential beneficial effects, but it also has paradoxical effects, which may be due to its inverted U-shape or pharmacokinetic features.",
            "score": 225.5127637386322
        },
        {
            "docid": "10548472_36",
            "document": "Neonicotinoid . Neonicotinoids, like nicotine, bind to nicotinic acetylcholine receptors (nAChRs) of a cell and trigger a response by that cell. In mammals, nicotinic acetylcholine receptors are located in cells of both the central nervous system and peripheral nervous systems. In insects these receptors are limited to the central nervous system. Nicotinic acetylcholine receptors are activated by the neurotransmitter acetylcholine. While low to moderate activation of these receptors causes nervous stimulation, high levels overstimulate and block the receptors, causing paralysis and death. Acetylcholinesterase breaks down acetylcholine to terminate signals from these receptors. However, acetylcholinesterase cannot break down neonicotinoids and their binding is irreversible.",
            "score": 250.39391016960144
        },
        {
            "docid": "73298_26",
            "document": "Tobacco smoking . The inhaled nicotine mimics nicotinic acetylcholine which when bound to nicotinic acetylcholine receptors prevents the reuptake of acetylcholine thereby increasing that neurotransmitter in those areas of the body. These nicotinic acetylcholine receptors are located in the central nervous system and at the nerve-muscle junction of skeletal muscles; whose activity increases heart rate, alertness, and faster reaction times. Nicotine acetylcholine stimulation is not directly addictive. However, since dopamine-releasing neurons are abundant on nicotine receptors, dopamine is released; and, in the nucleus accumbens, dopamine is associated with motivation causing reinforcing behavior. Dopamine increase, in the prefrontal cortex, may also increase working memory.",
            "score": 226.96565055847168
        },
        {
            "docid": "38272_33",
            "document": "Nicotine . Nicotine activates nicotinic receptors (particularly \u03b14\u03b22 nicotinic receptors) on neurons that innervate the ventral tegmental area and within the mesolimbic pathway where it appears to cause the release of dopamine. This nicotine-induced dopamine release occurs at least partially through activation of the cholinergic\u2013dopaminergic reward link in the ventral tegmental area. Nicotine also appears to induce the release of endogenous opioids that activate opioid pathways in the reward system, since naltrexone\u00a0\u2013 an opioid receptor antagonist\u00a0\u2013 blocks nicotine self-administration. These actions are largely responsible for the strongly reinforcing effects of nicotine, which often occur in the absence of euphoria; however, mild euphoria from nicotine use can occur in some individuals. Chronic nicotine use inhibits class I and II histone deacetylases in the striatum, where this effect plays a role in nicotine addiction.",
            "score": 223.5796685218811
        },
        {
            "docid": "12860292_11",
            "document": "Nicotinic agonist . \u03b17 receptors are homomeric neuronal acetylcholine receptors consisting of five \u03b17 subunits and has five ACh binding sites. Abnormality in the \u03b17 receptors expression have been reported to influence progression of diseases such as Alzheimer\u2019s disease and schizophrenia. The \u03b17 are not believed to have as much affinity for nicotine as the heteromeric receptor but instead they have shown more affinity for alpha bungarotoxin which is a nicotinic antagonist found in venom of some snakes. Targeting of \u03b17 receptors is therefore thought to be useful in treatment of Alzheimer\u2019s disease and schizophrenia.",
            "score": 188.6203055381775
        },
        {
            "docid": "57386068_8",
            "document": "Epigenetic effects of smoking . Exposure to cigarette smoke impacts proteins involved in DNA methylation. These effects come from either hypoxia induced by the cigarette smoke, or the chemical consequences of nicotine. Inhaling cigarette smoke increases blood levels of carbon monoxide which negatively affects oxygenation throughout the body leading to hypoxia. One response to hypoxia is the upregulation in synthesis of the major methyl donor S-adenosylmethionine. Upregulation of this methyl donor through heightened expression of methionine adenosyltransferase 2A leads to increased DNA methylation, which can lead to the down-regulation of target genes.  Nicotine found in cigarette smoke binds to nicotinic acetylcholine receptors.",
            "score": 221.64729928970337
        },
        {
            "docid": "38327_69",
            "document": "Cigarette . Tobacco contains nicotine. Smoking cigarettes can lead to nicotine addiction. The addiction begins when nicotine acts on nicotinic acetylcholine receptors to release neurotransmitters such as dopamine, glutamate, and gamma-aminobutyric acid. Cessation of smoking leads to symptoms of nicotine withdrawal such as anxiety and irritability. Professional smoking cessation support methods generally endeavour to address both nicotine addiction and nicotine withdrawal symptoms.",
            "score": 242.34259581565857
        },
        {
            "docid": "16859012_2",
            "document": "CHRNA6 . Cholinergic receptor, nicotinic, alpha 6, also known as nAChR\u03b16, is a protein that in humans is encoded by the \"CHRNA6\" gene. The CHRNA6 gene codes for the \u03b16 nicotinic receptor subunit that is found in certain types of nicotinic acetylcholine receptors found primarily in the brain. Neural nicotinic acetylcholine receptors containing \u03b16 subunits are expressed on dopamine-releasing neurons in the midbrain, and dopamine release following activation of these neurons is thought to be involved in the addictive properties of nicotine. Due to their selective localisation on dopaminergic neurons, \u03b16-containing nACh receptors have also been suggested as a possible therapeutic target for the treatment of Parkinson's disease.",
            "score": 210.9404489994049
        },
        {
            "docid": "173316_7",
            "document": "Strychnine . Strychnine is a neurotoxin which acts as an antagonist of glycine and acetylcholine receptors. It primarily affects the motor nerves in the spinal cord which control muscle contraction. An impulse is triggered at one end of a nerve by the binding of neurotransmitters to the receptors. In the presence of an inhibitory neurotransmitter, such as glycine, a greater quantity of excitatory neurotransmitters must bind to receptors before there will be an action potential generated. Glycine acts primarily as an agonist of the glycine receptor, which is a ligand-gated chloride channel in neurons located in the spinal cord and in the brain. This chloride channel will allow the negatively charged chloride ions into the neuron, causing a hyperpolarization which pushes the membrane potential further from threshold. Strychnine is an antagonist of glycine; it binds noncovalently to the same receptor, preventing the inhibitory effects of glycine on the postsynaptic neuron. Therefore, action potentials are triggered with lower levels of excitatory neurotransmitters. When the inhibitory signals are prevented, the motor neurons are more easily activated and the victim will have spastic muscle contractions, resulting in death by asphyxiation. Strychnine binds the \"Aplysia californica\" acetylcholine binding protein (a homolog of nicotinic receptors) with high affinity but low specificity, and does so in multiple conformations.",
            "score": 190.05781865119934
        },
        {
            "docid": "38272_14",
            "document": "Nicotine . A 2014 review found that nicotine use is not a significant cause of cardiovascular disease. A 2015 review found that nicotine is associated with cardiovascular disease. A 2016 review suggests that \"the risks of nicotine without tobacco combustion products (cigarette smoke) are low compared to cigarette smoking, but are still of concern in people with cardiovascular disease.\" Some studies in people show the possibility that nicotine contributes to acute cardiovascular events in smokers with established cardiovascular disease, and induces pharmacologic effects that might contribute to increased atherosclerosis. Prolonged nicotine use seems not to increase atherosclerosis. Brief nicotine use, such as nicotine medicine, seems to incur a slight cardiovascular risk, even to people with established cardiovascular disease. A 2015 review found \"Nicotine \"in vitro\" and in animal models can inhibit apoptosis and enhance angiogenesis, effects that raise concerns about the role of nicotine in promoting the acceleration of atherosclerotic disease.\" A 2012 Cochrane review found no evidence of an increased risk of cardiovascular disease with nicotine replacement products. A 1996 randomized controlled trial using nicotine patches found that serious adverse events were not more frequent among smokers with cardiovascular disease. A meta-analysis shows that snus consumption, which delivers nicotine at a dose equivalent to that of cigarettes, is not associated with heart attacks. Hence, it is not nicotine, but tobacco smoke's other components which seem to be implicated in ischemic heart disease. Nicotine increases heart rate and blood pressure and induces abnormal heart rhythms. Nicotine can also induce potentially atherogenic genes in human coronary artery endothelial cells. Microvascular injury can result through its action on nicotinic acetylcholine receptors (nAChRs). Nicotine does not adversely affect serum cholesterol levels, but a 2015 review found it may elevate serum cholesterol levels. Many quitting smoking studies using nicotine medicines report lowered dyslipidemia with considerable benefit in HDL/LDL ratios. Nicotine supports clot formation and aids in plaque formation by enhancing vascular smooth muscle.",
            "score": 245.9821240901947
        },
        {
            "docid": "12519951_8",
            "document": "Nitenpyram . Nitenpyram is a synthetic nicotine-related chemical (neonicotinoid), has an effect on the nicotinic acetylcholine receptors and are for this reason considered similar to nicotine (agonists). Nicotinic acetylcholine receptor is involved in the sympathic and parasympathic nervous systems, present on the muscle cells where the cells from the nervous systems and the muscle cells form synapses. Variations in nicotinic acetylcholine receptor binding affinity persists between species.",
            "score": 206.17779994010925
        },
        {
            "docid": "12719552_12",
            "document": "Nicotine dependence . Nicotine binds with nicotinic receptors in the brain and releases a variety of neurotransmitters, including dopamine, which, in turn, produce the pleasurable effects associated with smoking. With repeated exposure to nicotine, the number of binding sites on nicotinic receptors in the brain increases. When these receptors are not occupied by nicotine, they are believed to produce withdrawal symptoms. This upregulation or increase in the number of nicotinic receptors also significantly alters the functioning of the brain reward system. There are genetic risk factors for developing dependence. For instance, genetic markers for a specific type of nicotinic receptor (the \u03b15-\u03b13-\u03b24 nicotine receptors) have been linked to increased risk for dependence. In other words, for smokers with a specific genetic code, exposure to nicotine results in an increased risk for neuroadaptation and the development of nicotine dependence.",
            "score": 254.2835772037506
        },
        {
            "docid": "681908_3",
            "document": "Neuromuscular junction . Muscles require innervation to function\u2014and even just to maintain muscle tone, avoiding atrophy. Synaptic transmission at the neuromuscular junction begins when an action potential reaches the presynaptic terminal of a motor neuron, which activates voltage-dependent calcium channels to allow calcium ions to enter the neuron. Calcium ions bind to sensor proteins (synaptotagmin) on synaptic vesicles, triggering vesicle fusion with the cell membrane and subsequent neurotransmitter release from the motor neuron into the synaptic cleft. In vertebrates, motor neurons release acetylcholine (ACh), a small molecule neurotransmitter, which diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors (nAChRs) on the cell membrane of the muscle fiber, also known as the sarcolemma. nAChRs are ionotropic receptors, meaning they serve as ligand-gated ion channels. The binding of ACh to the receptor can depolarize the muscle fiber, causing a cascade that eventually results in muscle contraction.",
            "score": 253.41015923023224
        },
        {
            "docid": "52649_10",
            "document": "Acetylcholine . Nicotinic acetylcholine receptors are ligand-gated ion channels permeable to sodium, potassium, and calcium ions. In other words, they are ion channels embedded in cell membranes, capable of switching from a closed to a open state when acetylcholine binds to them; in the open state they allow ions to pass through. Nicotinic receptors come in two main types, known as muscle-type and neuronal-type. The muscle-type can be selectively blocked by curare, the neuronal-type by hexamethonium. The main location of muscle-type receptors is on muscle cells, as described in more detail below. Neuronal-type receptors are located in autonomic ganglia (both sympathetic and parasympathetic), and in the central nervous system.",
            "score": 174.70506143569946
        },
        {
            "docid": "1289426_10",
            "document": "Memantine . Memantine acts as a non-competitive antagonist at different neuronal nicotinic acetylcholine receptors (nAChRs) at potencies possibly similar to the NMDA and 5-HT3 receptors, but this is difficult to ascertain with accuracy because of the rapid desensitization of nAChR responses in these experiments. It can be noted that memantine is an antagonist at Alpha-7 nAChR, which may contribute to initial worsening of cognitive function during early memantine treatment. Alpha-7 nAChR upregulates quickly in response to antagonism, which could explain the cognitive-enhancing effects of chronic memantine treatment. It has been shown that the number of nicotinic receptors in the brain are reduced in Alzheimer's disease, even in the absence of a general decrease in the number of neurons, and nicotinic receptor agonists are viewed as interesting targets for anti-Alzheimer drugs.",
            "score": 263.9061698913574
        },
        {
            "docid": "569480_3",
            "document": "Receptor (biochemistry) . Receptor proteins can be classified by their location. Transmembrane receptors include ion channel-linked (ionotropic) receptors, G protein-linked (metabotropic) hormone receptors, and enzyme-linked hormone receptors. Intracellular receptors are those found inside the cell, and include cytoplasmic receptors and nuclear receptors. A molecule that binds to a receptor is called a ligand, and can be a protein or peptide (short protein), or another small molecule such as a neurotransmitter, hormone, pharmaceutical drug, toxin, or parts of the outside of a virus or microbe. The endogenously designated -molecule for a particular receptor is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine but the receptor can also be activated by nicotine and blocked by curare.",
            "score": 175.2162835597992
        },
        {
            "docid": "260578_6",
            "document": "Muscle relaxant . Muscle relaxation and paralysis can theoretically occur by interrupting function at several sites, including the central nervous system, myelinated somatic nerves, unmyelinated motor nerve terminals, nicotinic acetylcholine receptors, the motor end plate, and the muscle membrane or contractile apparatus. Most neuromuscular blockers function by blocking transmission at the end plate of the neuromuscular junction. Normally, a nerve impulse arrives at the motor nerve terminal, initiating an influx of calcium ions, which causes the exocytosis of synaptic vesicles containing acetylcholine. Acetylcholine then diffuses across the synaptic cleft. It may be hydrolysed by acetylcholine esterase (AchE) or bind to the nicotinic receptors located on the motor end plate. The binding of two acetylcholine molecules results in a conformational change in the receptor that opens the sodium-potassium channel of the nicotinic receptor. This allows and ions to enter the cell and ions to leave the cell, causing a depolarization of the end plate, resulting in muscle contraction. Following depolarization, the acetylcholine molecules are then removed from the end plate region and enzymatically hydrolysed by acetylcholinesterase.",
            "score": 193.6098085641861
        },
        {
            "docid": "654168_4",
            "document": "Receptor antagonist . Biochemical receptors are large protein molecules that can be activated by the binding of a ligand such as a hormone or a drug. Receptors can be membrane-bound, as cell surface receptors, or inside the cell as intracellular receptors, such as nuclear receptors including those of the mitochondrion. Binding occurs as a result of non-covalent interactions between the receptor and its ligand, at locations called the binding site on the receptor. A receptor may contain one or more binding sites for different ligands. Binding to the active site on the receptor regulates receptor activation directly. The activity of receptors can also be regulated by the binding of a ligand to other sites on the receptor, as in allosteric binding sites. Antagonists mediate their effects through receptor interactions by preventing agonist-induced responses. This may be accomplished by binding to the active site or the allosteric site. In addition, antagonists may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity to exert their effects.",
            "score": 146.9758986234665
        },
        {
            "docid": "12860292_23",
            "document": "Nicotinic agonist . The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine\u2019s positive effects on animal memory. The development of nicotinic acetylcholine receptor agonists has come a long way since then. The nicotinic acetylcholine receptor agonist are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction. Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.",
            "score": 218.60310983657837
        },
        {
            "docid": "4109042_18",
            "document": "Cell signaling . In some cases, receptor activation caused by ligand binding to a receptor is directly coupled to the cell's response to the ligand. For example, the neurotransmitter GABA can activate a cell surface receptor that is part of an ion channel. GABA binding to a GABA receptor on a neuron opens a chloride-selective ion channel that is part of the receptor. GABA receptor activation allows negatively charged chloride ions to move into the neuron, which inhibits the ability of the neuron to produce action potentials. However, for many cell surface receptors, ligand-receptor interactions are not directly linked to the cell's response. The activated receptor must first interact with other proteins inside the cell before the ultimate physiological effect of the ligand on the cell's behavior is produced. Often, the behavior of a chain of several interacting cell proteins is altered following receptor activation. The entire set of cell changes induced by receptor activation is called a signal transduction mechanism or pathway.",
            "score": 138.18131017684937
        },
        {
            "docid": "772258_2",
            "document": "Imidacloprid . Imidacloprid is a systemic insecticide that acts as an insect neurotoxin and belongs to a class of chemicals called the neonicotinoids which act on the central nervous system of insects. The chemical works by interfering with the transmission of stimuli in the insect nervous system. Specifically, it causes a blockage of the nicotinergic neuronal pathway. By blocking nicotinic acetylcholine receptors, imidacloprid prevents acetylcholine from transmitting impulses between nerves, resulting in the insect's paralysis and eventual death. It is effective on contact and via stomach action. Because imidacloprid binds much more strongly to insect neuron receptors than to mammal neuron receptors, this insecticide is more toxic to insects than to mammals.",
            "score": 167.99090337753296
        },
        {
            "docid": "546712_5",
            "document": "Neurotoxicity . A\u03b2 was found to cause neurotoxicity and cell death in the brain when present in high concentrations. A\u03b2 results from a mutation that occurs when protein chains are cut at the wrong locations, resulting in chains of different lengths that are unusable. Thus they are left in the brain until they are broken down, but if enough accumulate, they form plaques which are toxic to neurons. A\u03b2 uses several routes in the central nervous system to cause cell death. An example is through the nicotinic acetylcholine receptor (nAchRs), which is a receptor commonly found along the surfaces of the cells that respond to nicotine stimulation, turning them on or off. A\u03b2 was found manipulating the level of nicotine in the brain along with the MAP kinase, another signaling receptor, to cause cell death. Another chemical in the brain that A\u03b2 regulates is JNK; this chemical halts the extracellular signal-regulated kinases (ERK) pathway, which normally functions as memory control in the brain. As a result, this memory favoring pathway is stopped, and the brain loses essential memory function. The loss of memory is a symptom of neurodegenerative disease, including AD. Another way A\u03b2 causes cell death is through the phosphorylation of AKT; this occurs as the element phosphate is bound to several sites on the protein. This phosphorylation allows AKT to interact with BAD, a protein known to cause cell death. Thus an increase in A\u03b2 results in an increase of the AKT/BAD complex, in turn stopping the action of the anti-apoptotic protein Bcl-2, which normally functions to stop cell death, causing accelerated neuron breakdown and the progression of AD.",
            "score": 233.38296234607697
        },
        {
            "docid": "326357_21",
            "document": "Neurotoxin . Toxic effects from anatoxin-\"a\" progress very rapidly because it acts directly on the nerve cells (neurons). The progressive symptoms of anatoxin-\"a\" exposure are loss of coordination, twitching, convulsions and rapid death by respiratory paralysis. The nerve tissues which communicate with muscles contain a receptor called the nicotinic acetylcholine receptor. Stimulation of these receptors causes a muscular contraction. The anatoxin-\"a\" molecule is shaped so it fits this receptor, and in this way it mimics the natural neurotransmitter normally used by the receptor, acetylcholine. Once it has triggered a contraction, anatoxin-\"a\" does not allow the neurons to return to their resting state, because it is not degraded by cholinesterase which normally performs this function. As a result, the muscle cells contract permanently, the communication between the brain and the muscles is disrupted and breathing stops.",
            "score": 164.281081199646
        },
        {
            "docid": "1064680_20",
            "document": "Cyanotoxin . Toxic effects from anatoxin-\"a\" progress very rapidly because it acts directly on the nerve cells (neurons) as a neurotoxin. The progressive symptoms of anatoxin-\"a\" exposure are loss of coordination, twitching, convulsions and rapid death by respiratory paralysis. The nerve tissues which communicate with muscles contain a receptor called the nicotinic acetylcholine receptor. Stimulation of these receptors causes a muscular contraction. The anatoxin-\"a\" molecule is shaped so it fits this receptor, and in this way it mimics the natural neurotransmitter normally used by the receptor, acetylcholine. Once it has triggered a contraction, anatoxin-\"a\" does not allow the neurons to return to their resting state, because it is not degraded by cholinesterase which normally performs this function. As a result, the muscle cells contract permanently, the communication between the brain and the muscles is disrupted and breathing stops.",
            "score": 164.281081199646
        },
        {
            "docid": "14147566_24",
            "document": "Cobratoxin . In 2009 promising results showed that the acetylcholine receptor plays an import role in developing lung cancer. It is widely known that nicotine stimulates the tumor growth on our lungs. By binding to this receptor it activates some pathways which will block the apoptosis. As a consequence, unregulated cell proliferation occurs. This cell proliferation caused by nicotine could be blocked by using cobratoxin. Cobratoxin blocks the acetylchloline receptor because of the high affinity. Unfortunately, in 2011 this theory has been disproven. Mice treated with cobratoxin did not show any significant reduction in tumor growth. The conclusion of these results, in contrast with earlier results, was that the acetylcholine receptor inhibitors neither suppressed growth of the lung tumors nor prolonged the lives of the mice.",
            "score": 182.2429633140564
        },
        {
            "docid": "52649_9",
            "document": "Acetylcholine . Like many other biologically active substances, acetylcholine exerts its effects by binding to and activating receptors located on the surface of cells. There are two main classes of acetylcholine receptor, nicotinic and muscarinic. They are named for chemicals that can selectively activate each type of receptor without activating the other: muscarine is a compound found in the mushroom \"Amanita muscaria\"; nicotine is found in tobacco.",
            "score": 199.81933975219727
        },
        {
            "docid": "66391_37",
            "document": "Stimulant . Nicotine is the active chemical constituent in tobacco, which is available in many forms, including cigarettes, cigars, chewing tobacco, and smoking cessation aids such as nicotine patches, nicotine gum, and electronic cigarettes. Nicotine is used widely throughout the world for its stimulating and relaxing effects. Nicotine exerts its effects through the agonism of nicotinic acetylcholine receptor, resulting in multiple downstream effects such as increase in activity of dopaminergic neurons in the midbrain reward system, as well as the decreased expression of monoamine oxidase in the brain. Nicotine is addictive and dependence forming. The most common source of nicotine, tobacco's, overall harm to user and self score as determined by a multi-criteria decision analysis was determined at 3 percent below cocaine, and 13 percent above amphetamines, ranking 6th most harmful of the 20 drugs assessed.",
            "score": 247.89597868919373
        },
        {
            "docid": "5108068_3",
            "document": "Varenicline . It is a high-affinity partial agonist for the \u03b14\u03b22 nicotinic acetylcholine receptor subtype (nACH) that leads to the release of dopamine in the nucleus accumbens when activated, and therefore, has the capacity to reduce the feelings of craving and withdrawal caused by smoking cessation. In this respect it is similar to cytisine and different from the nicotinic antagonist bupropion and nicotine replacement therapies (NRTs) like nicotine patches and nicotine gum.",
            "score": 290.3770709037781
        },
        {
            "docid": "11011552_4",
            "document": "Cellular communication (biology) . Reception occurs when the target cell (any cell with a receptor protein specific to the signal molecule) detects a signal, usually in the form of a small, water-soluble molecule, via binding to a receptor protein. Reception is the target cell's detection of a signal via binding of a signaling molecule, or ligand. Receptor proteins span the cell\u2019s plasma membrane and provide specific sites for water-soluble signaling molecules to bind to. These trans-membrane receptors are able to transmit information from outside the cell to the inside because they change conformation when a specific ligand binds to it. By looking at three major types of receptors, (G protein coupled receptors, receptor tyrosine kinases, and ion channel receptors) scientists are able to see how trans-membrane receptors contribute to the complexity of cells and the work that these cells do. Cell surface receptors play an essential role in the biological systems of single- and multi-cellular organisms and malfunction or damage to these proteins is associated with cancer, heart disease, and asthma.",
            "score": 129.07163763046265
        },
        {
            "docid": "25505185_19",
            "document": "Schizophrenia and smoking . Another area of research is the role of nicotinic receptors in schizophrenia and smoking. Studies show increased numbers of exposed nicotinic receptors, which could explain the pathology of both smoking and schizophrenia. However, others argue that the increase in nicotinic receptors is a result of persistent heavy smoking, rather than schizophrenia.",
            "score": 179.51532769203186
        }
    ],
    "r": [
        {
            "docid": "5108068_17",
            "document": "Varenicline . Varenicline's partial agonism on the \u03b1\u03b2 receptors rather than nicotine's full agonism produces less effect of dopamine release than nicotine's. This \u03b1\u03b2 competitive binding reduces the ability of nicotine to bind and stimulate the mesolimbic dopamine system - similar to the method of action of buprenorphine in the treatment of opioid addiction.",
            "score": 314.2652893066406
        },
        {
            "docid": "4981862_2",
            "document": "Cytisine . Cytisine, also known as baptitoxine and sophorine, is an alkaloid that occurs naturally in several plant genera, such as \"Laburnum\" and \"Cytisus\" of the family Fabaceae. It has been used medically to help with smoking cessation. Its molecular structure has some similarity to that of nicotine and it has similar pharmacological effects. Like varenicline, cytisine is a partial agonist of nicotinic acetylcholine receptors (nAChRs). Cytisine has a short half-life of 4.8 hours, and is rapidly eliminated from the body. The use of cytisine for smoking cessation remains relatively unknown outside Eastern Europe.",
            "score": 298.8309631347656
        },
        {
            "docid": "12860292_14",
            "document": "Nicotinic agonist . Drugs that influence nAChRs can be agonists, partial agonists or antagonists. Agonists, e.g. nicotine, can however act as depolarizing agents when encountered to nAChRs for some time (seconds or minutes, depending on concentration and nAChR subtype), chronic exposure to agonist can also lead to long lasting functional deactivation because of rapid and persistent desensitization. Partial nAChR agonists have been studied since they seem to be helpful in smoking cessation. The partial agonists are believed to bind to the nAChRs and stimulate the release of dopamine in smaller portions than the agonists and therefore compensate for the absence of nicotine.The lack of specificity among some of the nicotinic agonists is well known and is a potential problem when using them to treat illnesses that require targeting a specific subtype of nAChRs. Among these nonspecific agonists are for example ACh, nicotine and epibatidine that all target more than one subtype of nAChRs.",
            "score": 295.25213623046875
        },
        {
            "docid": "5108068_3",
            "document": "Varenicline . It is a high-affinity partial agonist for the \u03b14\u03b22 nicotinic acetylcholine receptor subtype (nACH) that leads to the release of dopamine in the nucleus accumbens when activated, and therefore, has the capacity to reduce the feelings of craving and withdrawal caused by smoking cessation. In this respect it is similar to cytisine and different from the nicotinic antagonist bupropion and nicotine replacement therapies (NRTs) like nicotine patches and nicotine gum.",
            "score": 290.3770751953125
        },
        {
            "docid": "2982535_9",
            "document": "Habenular nuclei . According to the National Institute on Drug Abuse, 1 in 5 preventable deaths, in the United States, is caused by tobacco use. Nicotine is the addictive drug found in most tobacco products and is easily absorbed by the bloodstream of the body. Despite common misconceptions regarding the relaxing effects of tobacco and nicotine use, behavioral testing in animals has demonstrated nicotine to have an anxiogenic effect. Nicotinic acetylcholine receptors (nAChRs) have been identified as the primary site for nicotine activity and regulate consequent cellular polarization. nAChRs are made up a number of \u03b1 and \u03b2 subunits and are found in both the LHb and MHb, where research suggests they may play a key role in addiction and withdrawal behaviors.",
            "score": 288.5079345703125
        },
        {
            "docid": "27158894_44",
            "document": "Addiction . Another area in which drug treatment has been widely used is in the treatment of nicotine addiction, which usually involves the use of nicotine replacement therapy, nicotinic receptor antagonists, or nicotinic receptor partial agonists. Examples of drugs that act on nicotinic receptors and have been used for treating nicotine addiction include antagonists like bupropion and the partial agonist varenicline.",
            "score": 288.3318786621094
        },
        {
            "docid": "50012420_10",
            "document": "Jed Rose (scientist) . Rose aided in the conception of varenicline for smoking cessation: In the 1990s Rose et al. conducted clinical trials of an agonist-antagonist combination treatment, using nicotine (agonist) and mecamylamine (nicotinic antagonist). The combination proved more efficacious than either agent alone. Pfizer pharmaceuticals cited this work as helping to inspire the development of the partial nicotinic agonist varenicline, which is currently the most effective pharmacologic smoking cessation treatment available.",
            "score": 285.8326110839844
        },
        {
            "docid": "2103074_12",
            "document": "Epibatidine . Nicotinic acetylcholine receptors are found in the post-synaptic membranes of nerve cells. They propagate neurotransmission in the central and peripheral nervous system. When neurotransmitters bind to these receptors, ion channels open, allowing Na and Ca ions to move across the membrane. This depolarizes the post-synaptic membrane, inducing an action potential that propagates the signal. This signal will ultimately induce release of dopamine and norepinephrine, resulting in an antinociceptive effect on the organism. The usual neurotransmitter for nAChR is acetylcholine. However, other substances (such as epibatidine and nicotine) are also able to bind to the receptor and induce a similar, if not identical, response. Epibatidine has an extremely high affinity for nAChRs, depending on the receptor subtype, from 0.05\u00a0nM at the \u03b14\u03b22 subtype to 22\u00a0nM at the \u03b17 subtype. Affinity as well as efficacy (and thus also potency) are much higher than for nicotine.",
            "score": 280.9612121582031
        },
        {
            "docid": "14435251_5",
            "document": "Elbert Glover . Glover's primary research interest is the development of cessation aids for people interested in stopping the use of tobacco. As of 1987, he was study a recent in the increased use of smokeless tobacco. He has conducted clinical trials with the use of many delivery forms of nicotine available on the US and European markets, including gum, transdermal patches, oral nicotine inhalers, nasal spray, and sublingual tablets. Glover also conducted trials with bupropion (Zyban, a monocyclic antidepressant) and varenicline (Chantix, a nicotine receptor and partial agonist) which resulted in both being approved for use in the US. In addition, he has studied the use of lobeline as a nicotine blocker, and various psychoactive substances including anti-depressants and anti-anxiety agents. He has also investigated rimonabant (an endocabinnoid), varenicline (a nicotine receptor partial agonist) and 3\u2032AmNic-rEPA (a nicotine conjugate vaccine).",
            "score": 276.1203918457031
        },
        {
            "docid": "12719552_15",
            "document": "Nicotine dependence . There are eight major evidence-based medications for treating nicotine dependence: bupropion, cytisine (not approved for use in some countries, including the US), nicotine gum, nicotine inhaler, nicotine lozenge/mini-lozenge, nicotine nasal spray, nicotine patch, and varenicline. These medications have been shown to significantly improve long-term (i.e., 6-months post-quit day) abstinence rates, especially when used in combination with psychosocial treatment. The nicotine replacement treatments (i.e., patch, lozenge, gum) are dosed based on how dependent a smoker is\u2014people who smoke more cigarettes or who smoke earlier in the morning use higher doses of nicotine replacement treatments.",
            "score": 275.6335754394531
        },
        {
            "docid": "9126099_6",
            "document": "Nicotine withdrawal . Gradually reducing nicotine intake causes less withdrawal than abruptly stopping. Another way to reduce nicotine withdrawal symptoms is to provide the body with an alternative source of nicotine (nicotine replacement therapy) for a temporary period and then taper this new nicotine intake. Other medication used for quitting smoking include bupropion, varenicline, cytisine, nortriptyline, and clonidine. Treatments other than medication, such as increased exercise, can also reduce nicotine withdrawal. Many behavior changes such as avoiding situations where one usually smoked, planning ahead to deal with temptations, and seeking the support of friends and family are effective in helping people quit smoking, but whether this is due to reduced withdrawal is unclear.",
            "score": 271.920166015625
        },
        {
            "docid": "5108068_2",
            "document": "Varenicline . Varenicline (trade name Chantix and Champix), is a prescription medication used to treat nicotine addiction. It both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products.",
            "score": 270.63336181640625
        },
        {
            "docid": "17713911_2",
            "document": "Dianicline . Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the \u03b14\u03b22 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.",
            "score": 266.1002197265625
        },
        {
            "docid": "12860292_3",
            "document": "Nicotinic agonist . Examples include nicotine (by definition), acetylcholine (the endogenous agonist of nAChRs), choline, epibatidine, lobeline, varenicline and cytisine.",
            "score": 263.9143371582031
        },
        {
            "docid": "1289426_10",
            "document": "Memantine . Memantine acts as a non-competitive antagonist at different neuronal nicotinic acetylcholine receptors (nAChRs) at potencies possibly similar to the NMDA and 5-HT3 receptors, but this is difficult to ascertain with accuracy because of the rapid desensitization of nAChR responses in these experiments. It can be noted that memantine is an antagonist at Alpha-7 nAChR, which may contribute to initial worsening of cognitive function during early memantine treatment. Alpha-7 nAChR upregulates quickly in response to antagonism, which could explain the cognitive-enhancing effects of chronic memantine treatment. It has been shown that the number of nicotinic receptors in the brain are reduced in Alzheimer's disease, even in the absence of a general decrease in the number of neurons, and nicotinic receptor agonists are viewed as interesting targets for anti-Alzheimer drugs.",
            "score": 263.9061584472656
        },
        {
            "docid": "3585815_66",
            "document": "Health effects of tobacco . Nicotine, which is contained in cigarettes and other smoked tobacco products, is a stimulant and is one of the main factors leading to continued tobacco smoking. Nicotine is a highly addictive psychoactive chemical. When tobacco is smoked, most of the nicotine is pyrolyzed; a dose sufficient to cause mild somatic dependency and mild to strong psychological dependency remains. The amount of nicotine absorbed by the body from smoking depends on many factors, including the type of tobacco, whether the smoke is inhaled, and whether a filter is used. There is also a formation of harmane (a MAO inhibitor) from the acetaldehyde in cigarette smoke, which seems to play an important role in nicotine addiction probably by facilitating dopamine release in the nucleus accumbens in response to nicotine stimuli. According to studies by Henningfield and Benowitz, nicotine is more addictive than cannabis, caffeine, ethanol, cocaine, and heroin when considering both somatic and psychological dependence. However, due to the stronger withdrawal effects of ethanol, cocaine and heroin, nicotine may have a lower potential for somatic dependence than these substances.<ref name=\"urlRelative Addictiveness of Drugs (NYT 8/2/94)\"></ref> About half of Canadians who currently smoke have tried to quit. McGill University health professor Jennifer O'Loughlin stated that nicotine addiction can occur as soon as five months after the start of smoking.",
            "score": 261.5285339355469
        },
        {
            "docid": "6226648_36",
            "document": "Brain stimulation reward . Cholinergic drugs have been less extensively studied than monoamines and opioids. The most commonly studied cholinergic drug is nicotine, the highly-addictive, psychoactive substance in cigarettes. Nicotine is an agonist of nicotinic acetylcholine receptors (nAchRs), which are ligand-gated ion channels. The addictive properties of nicotine have been found to be associated with agonism specifically of the \u03b14\u03b22 sub-type of nicotinic receptors. Many studies have confirmed that low doses of nicotine result in ICSS facilitation, while higher doses result in ICSS depression. Chronic treatment with nicotine does not result in tolerance to ICSS facilitation at low doses, but does result in tolerance to the depressive effects of high doses. Withdrawal-induced depression of ICSS facilitation at low doses is also observed, as in MOR agonists and monoamine stimulants. It should be noted that the effects of nicotine treatment on ICSS response thresholds and maximum response rates are not as significant as they are in the case of many addictive MOR agonists and monoamine stimulants.",
            "score": 258.6251220703125
        },
        {
            "docid": "30206738_30",
            "document": "Chronic obstructive pulmonary disease . Some smokers can achieve long-term smoking cessation through willpower alone. Smoking, however, is highly addictive, and many smokers need further support. The chance of quitting is improved with social support, engagement in a smoking cessation program, and the use of medications such as nicotine replacement therapy, bupropion, or varenicline. Combining smoking-cessation medication with behavioral therapy is more than twice as likely to be effective in helping people with COPD stop smoking, compared with behavioral therapy alone.",
            "score": 257.9730529785156
        },
        {
            "docid": "743410_2",
            "document": "Nicotinic acetylcholine receptor . Nicotinic acetylcholine receptors, or nAChRs, are receptor proteins that respond to the neurotransmitter acetylcholine. Nicotinic receptors also respond to drugs, including the nicotinic receptor agonist nicotine. They are found in the central and peripheral nervous system, muscle, and many other tissues of many organisms, including humans. At the neuromuscular junction they are the primary receptor in muscle for motor nerve-muscle communication that controls muscle contraction. In the peripheral nervous system: (1) they transmit outgoing signals from the presynaptic to the postsynaptic cells within the sympathetic and parasympathetic nervous system, and (2) they are the receptors found on skeletal muscle that receive acetylcholine released to signal for muscular contraction. In the immune system, nAChRs regulate inflammatory processes and signal through distinct intracellular pathways. In insects, the cholinergic system is limited to the central nervous system.",
            "score": 257.1683349609375
        },
        {
            "docid": "326357_23",
            "document": "Neurotoxin . Bungarotoxin is a compound with known interaction with nicotinic acetylcholine receptors (nAChRs), which constitute a family of ion channels whose activity is triggered by neurotransmitter binding. Bungarotoxin is produced in a number of different forms, though one of the commonly used forms is the long chain alpha form, \u03b1-bungarotoxin, which is isolated from the banded krait snake. Though extremely toxic if ingested, \u03b1-bungarotoxin has shown extensive usefulness in neuroscience as it is particularly adept at isolating nAChRs due to its high affinity to the receptors. As there are multiple forms of bungarotoxin, there are different forms of nAChRs to which they will bind, and \u03b1-bungarotoxin is particularly specific for \u03b17-nAChR. This \u03b17-nAChR functions to allow calcium ion influx into cells, and thus when blocked by ingested bungarotoxin will produce damaging effects, as ACh signaling will be inhibited. Likewise, the use of \u03b1-bungarotoxin can be very useful in neuroscience if it is desirable to block calcium flux in order to isolate effects of other channels. Additionally, different forms of bungarotoxin may be useful for studying inhibited nAChRs and their resultant calcium ion flow in different systems of the body. For example, \u03b1-bungarotoxin is specific for nAChRs found in the musculature and \u03ba-bungarotoxin is specific for nAChRs found in neurons.",
            "score": 254.87539672851562
        },
        {
            "docid": "12719552_12",
            "document": "Nicotine dependence . Nicotine binds with nicotinic receptors in the brain and releases a variety of neurotransmitters, including dopamine, which, in turn, produce the pleasurable effects associated with smoking. With repeated exposure to nicotine, the number of binding sites on nicotinic receptors in the brain increases. When these receptors are not occupied by nicotine, they are believed to produce withdrawal symptoms. This upregulation or increase in the number of nicotinic receptors also significantly alters the functioning of the brain reward system. There are genetic risk factors for developing dependence. For instance, genetic markers for a specific type of nicotinic receptor (the \u03b15-\u03b13-\u03b24 nicotine receptors) have been linked to increased risk for dependence. In other words, for smokers with a specific genetic code, exposure to nicotine results in an increased risk for neuroadaptation and the development of nicotine dependence.",
            "score": 254.28358459472656
        },
        {
            "docid": "12860292_10",
            "document": "Nicotinic agonist . \u03b14\u03b22 nAChRs contain two \u03b14 subunits and three \u03b22 subunits, therefore it has two binding sites for ACh and other agonists. \u03b14\u03b22 nAChRs account for approximately 90% of the nAChRs in the human brain and when chronically exposed to nicotine or other nicotine agonists leads to increase in density of \u03b14\u03b22 receptors which is the opposite of what usually happens when other receptors are chronically exposed to their agonists. The \u03b14\u03b22 receptor has been widely studied in regards to Alzheimer\u2019s disease as well as for nicotine dependence and in 2009 several drugs are on the market that target the \u03b14\u03b22 nAChR specifically.",
            "score": 253.90785217285156
        },
        {
            "docid": "681908_3",
            "document": "Neuromuscular junction . Muscles require innervation to function\u2014and even just to maintain muscle tone, avoiding atrophy. Synaptic transmission at the neuromuscular junction begins when an action potential reaches the presynaptic terminal of a motor neuron, which activates voltage-dependent calcium channels to allow calcium ions to enter the neuron. Calcium ions bind to sensor proteins (synaptotagmin) on synaptic vesicles, triggering vesicle fusion with the cell membrane and subsequent neurotransmitter release from the motor neuron into the synaptic cleft. In vertebrates, motor neurons release acetylcholine (ACh), a small molecule neurotransmitter, which diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors (nAChRs) on the cell membrane of the muscle fiber, also known as the sarcolemma. nAChRs are ionotropic receptors, meaning they serve as ligand-gated ion channels. The binding of ACh to the receptor can depolarize the muscle fiber, causing a cascade that eventually results in muscle contraction.",
            "score": 253.41015625
        },
        {
            "docid": "5108068_7",
            "document": "Varenicline . Varenicline has not been tested in those under 18 years old or pregnant women and therefore is not recommended for use by these groups. Varenicline is considered a class C pregnancy drug, as animal studies have shown no increased risk of congenital anomalies, however, no data from human studies is available. An observational study is currently being conducted assessing for malformations related to varenicline exposure, but has no results yet. An alternate drug is preferred for smoking cessation during breastfeeding due to lack of information and based on the animal studies on nicotine.",
            "score": 252.9917755126953
        },
        {
            "docid": "1214927_13",
            "document": "Galantamine . Galantamine is a potent allosteric potentiating ligand of human nicotinic acetylcholine receptors (nAChRs) \u03b1\u03b2, \u03b1\u03b2, and \u03b1\u03b2, and chicken/mouse nAChRs \u03b1/5-HT in certain areas of the brain. By binding to the allosteric site of the nAChRs, a conformational change occurs which increases the receptors response to acetylcholine. This modulation of the nicotinic cholinergic receptors on cholinergic neurons in turn causes an increase in the amount of acetylcholine released. Galantamine also works as a weak competitive and reversible cholinesterase inhibitor in all areas of the body. By inhibiting acetylcholinesterase, it increases the concentration and thereby action of acetylcholine in certain parts of the brain. Galantamine's effects on nAChRs and complementary acetylcholinesterase inhibition make up a dual mechanism of action. It is hypothesized that this action might relieve some of the symptoms of Alzheimer's.",
            "score": 251.70321655273438
        },
        {
            "docid": "21445461_35",
            "document": "Nonsynaptic plasticity . Drugs of abuse typically affect the mesolimbic system, or more specifically, the reward pathway of the nervous system. Amongst the common drugs of abuse, nicotine is one of the strongest agonists at the nicotinic cholinergic synapse. Nicotine, competing with acetylcholine (ACh), acts through the nonsynaptic, preterminal, nicotinic acetylcholine receptor (nAChRs) to initiate a membrane potential change and propagate an intracellular Ca signal, thus encouraging the release of neurotransmitters. The specific and characteristic role of calcium current mediated nAChR activity has a different voltage-dependence than other Ca permeable ion channels, as well as different temporal and spatial distribution and as a result, the nonsynaptic nAChR activity enhances the induction of synaptic potentiation, promoting the learning of substance dependence.",
            "score": 251.23899841308594
        },
        {
            "docid": "10548472_36",
            "document": "Neonicotinoid . Neonicotinoids, like nicotine, bind to nicotinic acetylcholine receptors (nAChRs) of a cell and trigger a response by that cell. In mammals, nicotinic acetylcholine receptors are located in cells of both the central nervous system and peripheral nervous systems. In insects these receptors are limited to the central nervous system. Nicotinic acetylcholine receptors are activated by the neurotransmitter acetylcholine. While low to moderate activation of these receptors causes nervous stimulation, high levels overstimulate and block the receptors, causing paralysis and death. Acetylcholinesterase breaks down acetylcholine to terminate signals from these receptors. However, acetylcholinesterase cannot break down neonicotinoids and their binding is irreversible.",
            "score": 250.39390563964844
        },
        {
            "docid": "6818170_5",
            "document": "NicVAX . NicVAX is a relapse prevention therapy designed to stimulate the immune system to produce antibodies that bind to nicotine in the bloodstream and prevent and/or slow it from crossing the blood\u2013brain barrier and entering the brain. With a reduced amount of nicotine reaching the brain, neurotransmitter release is greatly lessened and the pleasurable, positive-reinforcing effects of nicotine are diminished. Pre-clinical studies with the vaccine have shown that vaccination slows and decreases the amount of nicotine that reaches the brain and blocks the effects of nicotine, including effects that can reinforce and maintain addiction in animals. Therefore, if a recently quit tobacco smoker is vaccinated and has a tobacco cigarette after the immunization series is completed, the antibodies generated by the vaccine bind nicotine and alter its distribution into the brain. Because not enough nicotine enters the brain, addiction-relevant neural pathways are not activated. No pleasure is derived from the tobacco cigarette and the vaccinated subject does not relapse and begin smoking again.",
            "score": 250.3883514404297
        },
        {
            "docid": "378579_6",
            "document": "Bupropion . The next most common use is as an aid for smoking cessation. Bupropion reduces the severity of nicotine cravings and withdrawal symptoms. Bupropion is helpful for smoking cessation in smokers with no history of depression; thus, the effectiveness of bupropion is not due to its antidepressant effect. A typical bupropion treatment course lasts up to twelve weeks, with people halting the use of tobacco about ten days into the course. Bupropion approximately doubles the chance of quitting smoking successfully. The effectiveness of bupropion is comparable to nicotine replacement therapy, but less effective than varenicline.",
            "score": 249.1658935546875
        },
        {
            "docid": "1182816_15",
            "document": "World No Tobacco Day . Unlike the tobacco industry, some major pharmaceutical companies do publicly support WNTD. For example, Pfizer was a large sponsor for many WNTD events in the United Arab Emirates in 2008. At the time, Pfizer was preparing to release its drug Chantix (Varenicline) into the Middle Eastern market. The drug was \u201cdesigned to activate the nicotinic receptor to reduce both the severity of the smoker's craving and the withdrawal symptoms from nicotine.\u201d",
            "score": 248.02732849121094
        },
        {
            "docid": "66391_37",
            "document": "Stimulant . Nicotine is the active chemical constituent in tobacco, which is available in many forms, including cigarettes, cigars, chewing tobacco, and smoking cessation aids such as nicotine patches, nicotine gum, and electronic cigarettes. Nicotine is used widely throughout the world for its stimulating and relaxing effects. Nicotine exerts its effects through the agonism of nicotinic acetylcholine receptor, resulting in multiple downstream effects such as increase in activity of dopaminergic neurons in the midbrain reward system, as well as the decreased expression of monoamine oxidase in the brain. Nicotine is addictive and dependence forming. The most common source of nicotine, tobacco's, overall harm to user and self score as determined by a multi-criteria decision analysis was determined at 3 percent below cocaine, and 13 percent above amphetamines, ranking 6th most harmful of the 20 drugs assessed.",
            "score": 247.89598083496094
        },
        {
            "docid": "289607_32",
            "document": "Smoking cessation . A 2008 systematic review in the \"European Journal of Cancer Prevention\" found that group behavioural therapy was the most effective intervention strategy for smoking cessation, followed by bupropion, intensive physician advice, nicotine replacement therapy, individual counselling, telephone counselling, nursing interventions, and tailored self-help interventions; the study did not discuss varenicline. Quitting can be harder for individuals with dark pigmented skin compared to individuals with pale skin since nicotine has an affinity for melanin-containing tissues. Studies suggest this can cause the phenomenon of increased nicotine dependence and lower smoking cessation rate in darker pigmented individuals.",
            "score": 247.8928985595703
        }
    ]
}